Substance misuse in patients with schizophrenia: epidemiology and management.
about
A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidityRevisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behaviorThe neural correlates of implicit sequence learning in schizophrenia.In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia.Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.Stressing schizotypy: the modulating role of stress-relieving behaviours and intellectual capacity on functional hemispheric asymmetry.Comorbidity and pattern of substance use in hospitalized psychiatric patients.Perceived reasons for and consequences of substance abuse among patients with psychosisContinuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cuesSubstance abuse in patients with schizophrenia.Screening for substance use disorders in first-episode psychosis: implications for readmission.Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers.Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.Impact of substance use disorder on presentation and short-term course of schizophrenia.Pharmacological treatment of schizophrenia with comorbid substance use disorder.Patterns, predictors and impact of substance use in early psychosis: a longitudinal study.Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia.Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study.Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic reviewHow is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis.Involuntary hospitalization of first-episode psychosis with substance abuse during a 2-year follow-up.Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study.Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder.A qualitative study of illicit and non-prescribed drug use amongst people with psychotic disorders.Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness.The Role of Serine Racemase in the Pathophysiology of Brain Disorders.Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?Working memory and depressive symptoms in patients with schizophrenia and substance use disorders.Patients with nonaffective psychosis are at increased risk for heroin use disorders.Corpus callosum volumes in the 5 years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation.Correlates of victimisation amongst people with psychosisEnvironmental Risk Factors for Schizophrenia
P2860
Q24795358-78A3CB6B-17FD-438D-84BA-A234E3E7AF50Q26801102-4D8D057E-B33E-4A4A-A869-77C556BA055AQ30492567-3160BC0D-5E7E-45BE-B122-70A4472749DCQ30873588-B9AA5C16-79EE-4488-A73D-85A5FD81484EQ33762494-4B011566-2145-4DBD-828D-A0B86E52C453Q34155235-AF0899E7-680F-44BA-BD6D-E756C5E83022Q34461463-7CB81361-C1B8-4A07-8307-50024DE4B5C7Q34516286-D3C5A12E-877E-4E91-B910-03D0DF12BE00Q34820251-9E34210F-BFDB-4486-B63B-C309E7B440FBQ35236689-EC3435E3-3F91-4114-A358-2A74DC4D0657Q35323897-B5B5F706-96FC-4289-8D5D-877233BC29C8Q35600223-BF554805-A298-4C81-A71A-39504D16121CQ36059843-00E51F8D-E7A2-47A2-A929-9D243A7CDDB9Q36580033-EF758E9F-E43F-480C-9F4B-1A6B9CA97F9AQ36843962-06F625CF-346D-448E-8633-20C168439B0BQ37719233-739BD4FE-68E4-4B79-AADA-B6D482911051Q38658672-F56BF562-89B4-4CED-BD1C-9FD7A1DD6251Q39789560-1D20FB10-C251-4BA2-AC8F-DEAAAC84BBDFQ40175951-4A291930-1A5F-4531-A675-54C00A7F2368Q41040248-5DDD82B8-2773-473B-B419-C0C14AB62A77Q41437823-1332DD0E-2461-4714-A319-B6F9B2EA6480Q41664978-A722D350-29E2-4AD1-BE53-57D5CE6056D1Q43100062-C37FAB1C-38D9-49F4-B2EE-DE3E0D9FCCEEQ43543206-8DB8E278-DA91-470B-9D78-05D0EDFB8D8BQ46478883-66EFCA79-1E4C-4BB6-A4F7-3589CF10C6ADQ46831405-83E173FC-BAC7-4FA1-91B1-1C06F6822C89Q46857400-1A778CF3-C697-46ED-BFC5-5E4CA293E0E2Q48218575-2B43EDBC-9FD4-48A9-89FA-09ACADBD6CE2Q50130680-B5A88FCD-61E8-4B8B-856F-7F6254B3C59FQ50138246-21C6354A-AA21-4F6B-83AC-1BCC0ECA7E5FQ50935734-3E532D8D-F2B7-4B2E-BBF8-E43846CA30F0Q51952571-0CE61288-9F2A-4197-B5A7-582ED9ED0CA9Q52300369-41523D05-640C-416D-B9DB-E0DCEFBB2137Q54965265-D63566D5-E79A-4899-9A3C-80F3CD82ED67Q57149284-204029ED-AA44-439F-B933-F9F58D61F5FAQ57403291-85A1584F-964A-4363-AC6C-3269D4E23D2C
P2860
Substance misuse in patients with schizophrenia: epidemiology and management.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Substance misuse in patients with schizophrenia: epidemiology and management.
@ast
Substance misuse in patients with schizophrenia: epidemiology and management.
@en
Substance misuse in patients with schizophrenia: epidemiology and management.
@nl
type
label
Substance misuse in patients with schizophrenia: epidemiology and management.
@ast
Substance misuse in patients with schizophrenia: epidemiology and management.
@en
Substance misuse in patients with schizophrenia: epidemiology and management.
@nl
prefLabel
Substance misuse in patients with schizophrenia: epidemiology and management.
@ast
Substance misuse in patients with schizophrenia: epidemiology and management.
@en
Substance misuse in patients with schizophrenia: epidemiology and management.
@nl
P2093
P1433
P1476
Substance misuse in patients with schizophrenia: epidemiology and management.
@en
P2093
David J Kavanagh
Dianne Clark
Glenys Dore
John B Saunders
P304
P356
10.2165/00003495-200262050-00003
P577
2002-01-01T00:00:00Z
P6179
1004477430